Also, Rautenberg and colleagues proposed peripheral blood WT1 expression as a pre-transplant MRD marker, predicting post-transplant outcome and, hence, improving peri-transplant management in high-risk AML/MDS patients [34]. This evidence concerns the gene WT1 and acute myeloid leukemia.